2004
DOI: 10.1093/humrep/deh312
|View full text |Cite
|
Sign up to set email alerts
|

Use of the concomitant serum dosage of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions

Abstract: The concomitant dosage of CA 125, CA 19-9 and IL-6 does not add significant information in respect to the CA 125 test alone in diagnosing either early or advanced stages of endometriosis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

15
75
2
9

Year Published

2011
2011
2022
2022

Publication Types

Select...
3
3
2

Relationship

0
8

Authors

Journals

citations
Cited by 116 publications
(101 citation statements)
references
References 23 publications
15
75
2
9
Order By: Relevance
“…Nevertheless, elevated serum CA125 levels are only seen in 50% of patients presented with early stage ovarian cancer and 80%-90% of patients with late stage disease, thus limiting its sensitivity (Molina et al, 1992;Rosen et al, 2005). Furthermore, the utility of CA125 as a biomarker for detecting ovarian cancer is hindered by the documented lack of specificity, since elevated serum CA125 concentrations can be found not only in a broad range of benign gynecologic diseases, but also in malignancies of different origin, including non-ovarian gynecologic cancers, other epithelial tumors and nonepithelial malignancies (Buamah, 2000;Miralles et al, 2003;Somigliana et al, 2004;Molina et al, 2008;Park et al, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…Nevertheless, elevated serum CA125 levels are only seen in 50% of patients presented with early stage ovarian cancer and 80%-90% of patients with late stage disease, thus limiting its sensitivity (Molina et al, 1992;Rosen et al, 2005). Furthermore, the utility of CA125 as a biomarker for detecting ovarian cancer is hindered by the documented lack of specificity, since elevated serum CA125 concentrations can be found not only in a broad range of benign gynecologic diseases, but also in malignancies of different origin, including non-ovarian gynecologic cancers, other epithelial tumors and nonepithelial malignancies (Buamah, 2000;Miralles et al, 2003;Somigliana et al, 2004;Molina et al, 2008;Park et al, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…In comparative studies, those markers were not superior to CA-125 in relation to diagnostic performance in endometriosis. However, no serum biomarkers have been validated for a noninvasive diagnostic test with adequate sensitivity and specificity [13,14]. The purpose of our study was to improve the diagnostic performance of CA-125 by measuring the difference between the values of this biomarker collected in menstruation and in midcycle.…”
Section: Discussionmentioning
confidence: 99%
“…O método laboratorial utilizado para as dosagens das interleucinas 1-ß e 6 e do SAA foi o ELISA, ténica de ensaio imunoenzimático quantitativo tipo sanduíche: anticorpo-antígeno-anticorpo conjugado 3,6 . Anticorpos monoclonais específicos para as interleucinas foram pré-fixados em uma placa de ELISA.…”
Section: Métodos Laboratoriaisunclassified
“…Parte dos autores observaram valores superiores para a IL-1 na fase lútea, e não encontraram diferença entre as concentrações de IL-6 nas duas fases do ciclo; a SAA não foi avaliada previamente frente à fase do ciclo 3,24 .…”
Section: As Concentrações Séricas E Peritoneais Dos Mediadores Inflamunclassified
See 1 more Smart Citation